<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Managing an episode of acute uterine bleeding</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Managing an episode of acute uterine bleeding</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Managing an episode of acute uterine bleeding</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard A Zacur, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>An episode of acute (ie, heavy or prolonged) uterine bleeding may occur in reproductive-age patients with either ovulatory or anovulatory bleeding and often results in the need for urgent evaluation in a clinician's office or emergency department. Consequences of such bleeding depend on the volume of bleeding and range from inconvenience to the patient or interference with daily activities, to severe anemia with hypovolemia. Evaluation and management of patients experiencing acute uterine bleeding must be expedited to prevent or treat excessive blood loss.</p><p>Evaluation and management of an acute episode of heavy or prolonged uterine bleeding in a reproductive-age patient will be reviewed here. Causes of abnormal uterine bleeding, the evaluation and management of chronic abnormal uterine bleeding, uterine bleeding in pregnancy or in postmenopausal patients, and the approach to patients with a nonuterine source of vaginal bleeding in the emergency department are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6799.html" rel="external">"Evaluation and differential diagnosis of vaginal bleeding before 20 weeks of gestation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5421.html" rel="external">"Approach to the patient with postmenopausal uterine bleeding"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/286.html" rel="external">"Approach to the adult with vaginal bleeding in the emergency department"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>While there are standard definitions of normal and abnormal menstrual bleeding  (<a class="graphic graphic_table graphicRef103238" href="/d/graphic/103238.html" rel="external">table 1</a>), there is no standard definition of acute uterine bleeding. Suggested definitions include:</p><p class="bulletIndent1"><span class="glyph">●</span>Excessively heavy or prolonged bleeding of uterine origin sufficient in volume as to require urgent or emergency intervention [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding that is profuse and soaks a large sanitary pad or tampon at every hour or two and continues for two or more hours [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">While United States regulations specify that each regular to super plus tampon absorbs 6 to 15 g of fluid, which equals approximately 6 to 15 mL of whole blood [<a href="#rid3">3,4</a>], assessing the volume of blood loss by counting tampons or pads appears to be inaccurate. Clinical studies have reported that the absorbency varies greatly for different types of sanitary products and even for products within a single package [<a href="#rid5">5</a>]. For research purposes, the alkaline hematin method is the standard for determining menstrual blood loss from a tampon or sanitary pad; this is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'Definitions'</a>.)</p><p></p><p>In this topic, we will use the term acute to refer to bleeding that is either profuse or prolonged. We also will apply this term to reproductive-age patients with either ovulatory or anovulatory bleeding and those with isolated or recurrent episodes of acute bleeding.</p><p class="headingAnchor" id="H2315523028"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Causes of acute uterine bleeding in nonpregnant patients include anatomic uterine abnormalities (eg, fibroids, arteriovenous malformation), endocrinologic abnormalities (eg, ovulatory or thyroid dysfunction), or bleeding diatheses  (<a class="graphic graphic_figure graphicRef90483" href="/d/graphic/90483.html" rel="external">figure 1</a>) and are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5440.html" rel="external">"Causes of female genital tract bleeding", section on 'Uterine bleeding'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Patients with acute uterine bleeding generally report bleeding that may soak through clothing or onto bedding. Patients also often report passing blood clots. The current episode may represent either a new onset of bleeding or an exacerbation of existing bleeding; it may be continuous or intermittent. A hiatus of bleeding of several hours may represent blood that has accumulated in the upper vagina and is released when the patient changes position from supine or seated to standing.</p><p>Patients may also present with symptoms suggestive of heavy blood loss including feeling dizzy, faint, or having loss of consciousness.</p><p class="headingAnchor" id="H4"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H3167800253"><span class="h2">Initial evaluation of all patients</span><span class="headingEndMark"> — </span>The goals of the initial evaluation of a patient with acute uterine bleeding are to:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Establish hemodynamic stability</strong> – Initial evaluation includes assessment of hemodynamic stability since hemodynamically unstable patients (eg, tachycardic, hypotensive, orthostatic) require immediate supportive measures (eg, blood transfusion) and an expedited assessment (eg, laboratory testing may be performed prior to the history and physical examination; sonographic imaging may be deferred as brisk uterine bleeding may make it difficult to perform or interpret). However, in young healthy patients, vital signs, including postural changes, may be normal early in the course of significant bleeding due to compensatory mechanisms [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exclude pregnancy</strong> – The evaluation of pregnant patients with vaginal bleeding is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6799.html" rel="external">"Evaluation and differential diagnosis of vaginal bleeding before 20 weeks of gestation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify the source of bleeding</strong> – The evaluation of patients who present to the emergency department with a nonuterine source of acute vaginal bleeding are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/286.html" rel="external">"Approach to the adult with vaginal bleeding in the emergency department"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluate the volume of blood loss</strong> – On physical examination, the presence and volume of bleeding from the cervical os and blood or blood clots in the vaginal vault is noted. A hemoglobin/hematocrit is sent to assess for anemia and clotting studies are sent in patients with suspected coagulopathy. A bleeding diathesis may be either the etiology of the bleeding or may be secondary to other factors associated with the bleeding. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Further evaluation of hemodynamically stable patients</span><span class="headingEndMark"> — </span>Further evaluation of hemodynamically stable patients includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>History and physical examination</strong> – A complete history and physical examination is performed to confirm the uterus is the source of, and identify possible etiologies of, the bleeding. (See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'History'</a> and  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'Physical examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional laboratories</strong> – In addition to the above laboratories, a serum thyroid-stimulating hormone (TSH) level should be performed if thyroid disease is suspected. (See <a class="local">'Initial evaluation of all patients'</a> above and  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'Heavy menstrual bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify structural abnormalities</strong> – Uterine structural abnormalities can be identified with pelvic examination and/or pelvic imaging. Pelvic ultrasound is the imaging study of choice as it can be performed quickly, is relatively inexpensive, and is a sensitive method for detecting uterine pathology. (See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'Imaging: Choice of modality'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of the endometrium</strong> – Evaluation of the endometrium (typically with endometrial sampling) should be performed in select nonpregnant reproductive-aged patients and all postmenopausal patients who have an episode of acute uterine bleeding  (<a class="graphic graphic_table graphicRef58600" href="/d/graphic/58600.html" rel="external">table 2</a>), to exclude endometrial hyperplasia/neoplasia or, less commonly, endometritis. Whether sampling is performed before, during, or after treatment depends on the choice of initial therapy (ie, uterine curettage is both diagnostic and therapeutic) and whether the patient's hemodynamic status allows therapy to be deferred while sampling is performed. It is preferable to collect an endometrial specimen prior to hormonal therapy whenever possible, since hormonal alterations may interfere with interpretation of the sample. (See  <a class="medical medical_review" href="/d/html/3254.html" rel="external">"Endometrial sampling procedures"</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">MANAGING HEMODYNAMICALLY UNSTABLE PATIENTS</span><span class="headingEndMark"> — </span>Hemodynamically unstable patients with acute uterine bleeding require immediate intervention  (<a class="graphic graphic_algorithm graphicRef135253" href="/d/graphic/135253.html" rel="external">algorithm 1</a>). Such patients who present to an ambulatory setting should be transferred immediately to an acute care setting.</p><p class="headingAnchor" id="H15"><span class="h2">Stabilizing the patient</span><span class="headingEndMark"> — </span>Patients with hemodynamic instability require vascular access and blood product replacement  (<a class="graphic graphic_table graphicRef93934 graphicRef53854" href="/d/graphic/93934.html" rel="external">table 3A-B</a>). Intravenous (IV) fluids may be given to hypotensive patients but are generally avoided in patients with hemorrhage given the increased risk of coagulopathy from dilution of clotting factors and platelets. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a> and  <a class="medical medical_review" href="/d/html/113837.html" rel="external">"Initial management of moderate to severe hemorrhage in the adult trauma patient", section on 'Initial management of hemorrhage'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Therapeutic measures</span></p><p class="headingAnchor" id="H19"><span class="h3">Preferred: Uterine curettage</span><span class="headingEndMark"> — </span>For hemodynamically unstable patients with acute uterine bleeding, uterine curettage is the treatment of choice. One exception is patients with an arteriovenous (AV) malformation of the uterus; these patients may be managed differently. (See <a class="local">'Role of uterine artery embolization'</a> below.)</p><p>In most patients and at most institutions, uterine curettage can be performed rapidly, with cessation or significant decrease in bleeding in less than one hour. Other advantages of uterine curettage are that it is both diagnostic and therapeutic and it can be performed in patients who may desire future childbearing. A disadvantage of curettage is that it does not treat the underlying cause of uterine bleeding, so bleeding is likely to recur if no preventive therapy is initiated postoperatively [<a href="#rid7">7,8</a>].</p><p>There are no high-quality data comparing uterine curettage with medical therapy in patients with acute uterine bleeding. According to indirect data and clinical experience, medical therapy requires more time until bleeding subsides, but avoids the risk of perioperative complications [<a href="#rid7">7</a>]. Medical therapy is often beneficial in addition to curettage if bleeding persists after the procedure or to prevent recurrent bleeding. (See <a class="local">'Alternative: High-dose intravenous estrogen'</a> below.)</p><p>When curettage is performed, it can be done using a standard dilation and curettage (D&amp;C) or a Karman cannula. Advantages of the Karman cannula are that it can be used in the office or emergency department and often does not require cervical dilation. However, the Karman procedure typically removes less tissue and, thus, it may be less effective at decreasing bleeding. The steps of each procedure are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3254.html" rel="external">"Endometrial sampling procedures"</a> and  <a class="medical medical_review" href="/d/html/3273.html" rel="external">"Dilation and curettage"</a>.)</p><p class="headingAnchor" id="H1778605971"><span class="h4">Role of intrauterine tamponade</span><span class="headingEndMark"> — </span>Intrauterine tamponade may be used in conjunction with administration of blood products to stabilize the patient while more definitive therapy (eg, transfer to a high-acuity setting, preparation for uterine curettage, arrival of a surgeon) is implemented, or after completion of uterine curettage should bleeding continue. </p><p>Intrauterine tamponade can be achieved using either an intrauterine balloon or gauze packing. The steps for placing either of these are:</p><p class="bulletIndent1"><span class="glyph">●</span>Place a speculum in the vagina and visualize the cervical os.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sterilize the cervix by swabbing it three times with a large cotton swab or gauze soaked in iodine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stabilize the cervix by placing a single-tooth tenaculum or ring forceps on the anterior cervical lip.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grasp the balloon or gauze with a long Kelly or ring forceps and thread it in through the cervical os into the uterus.</p><p></p><p class="bulletIndent1">When a balloon is used, it is inflated after it is inserted into the uterus. A 30 mL Foley catheter is typically used; if brisk bleeding continues and the uterus is enlarged (eg, equivalent to ≥12 weeks of gestation), a larger balloon (eg, Bakri Cook balloon with a 500 mL capacity  (<a class="graphic graphic_figure graphicRef52635" href="/d/graphic/52635.html" rel="external">figure 2</a>)) may be required but should be avoided in adolescent patients [<a href="#rid9">9</a>]. Other balloons are available but have almost exclusively been used in patients with postpartum hemorrhage; thus, experience in nonpregnant patients is limited. (See  <a class="medical medical_review" href="/d/html/4440.html" rel="external">"Postpartum hemorrhage: Use of an intrauterine hemorrhage-control device", section on 'Intrauterine balloon tamponade'</a>.)</p><p></p><p class="bulletIndent1">When gauze is used, a continuous piece of gauze (eg, Kerlix) is preferred over smaller gauze pieces to avoid retained pieces of gauze upon removal. Specialized hemostatic gauze may also be used and is described separately (see  <a class="medical medical_review" href="/d/html/4440.html" rel="external">"Postpartum hemorrhage: Use of an intrauterine hemorrhage-control device", section on 'Intrauterine packing'</a>). Gauze is placed until no further gauze can be admitted. Firm, but not excessive, pressure is used to avoid uterine perforation. The gauze can be impregnated with 5000 units thrombin in 5 mL sterile <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> to enhance clotting. If packing does not control hemorrhage, in our clinical experience, repacking is unlikely to be effective. </p><p></p><p>The distended tamponaded uterus causes discomfort, which can be treated with analgesics or a slight reduction in distending pressure, as long as tamponade is maintained. Devices used to tamponade the uterus should not be left in place for more than 24 hours. If the tamponade is not removed for the purpose of other treatment measures, then deflation is performed slowly (eg, removal of 20 mL/hour for a balloon or removal of 5 cm/hour for gauze). We give broad-spectrum antibiotics for infection prophylaxis to patients with an intrauterine balloon or packing in place. (See  <a class="medical medical_review" href="/d/html/4440.html" rel="external">"Postpartum hemorrhage: Use of an intrauterine hemorrhage-control device", section on 'Postplacement care'</a>.)</p><p>This technique is generally similar to that of intrauterine tamponade in a postpartum patient with hemorrhage, which is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4440.html" rel="external">"Postpartum hemorrhage: Use of an intrauterine hemorrhage-control device"</a>.)</p><p class="headingAnchor" id="H1147404766"><span class="h3">Alternative: High-dose intravenous estrogen</span><span class="headingEndMark"> — </span>For hemodynamically unstable patients with acute uterine bleeding in whom a waiting period of three or more hours is not likely to result in the need for additional blood product transfusion or medical complications, we suggest medical therapy with high-dose IV <a class="drug drug_general" data-topicid="9424" href="/d/drug information/9424.html" rel="external">conjugated equine estrogen</a> (CEE) therapy. This therapy should be avoided in patients with absolute contraindications to estrogen therapy. (See <a class="local">'Patients at risk of thrombosis'</a> below.)</p><p>The American College of Obstetricians and Gynecologists (ACOG) recommends CEE 25 mg intravenously every four to six hours, for 24 hours [<a href="#rid10">10</a>]. The minimum effective dose should be administered to minimize side effects (eg, emesis) and risk of complications (eg, venous thromboembolism [<a href="#rid11">11</a>]). IV estrogen appears to result in cessation of bleeding in most patients within five hours of the first dose by promoting rapid regrowth of the denuded endometrium, stabilizing lysosomal membranes, and stimulating proliferation of endometrial ground substance [<a href="#rid7">7</a>]. In a randomized trial including 34 patients with excessive or prolonged uterine bleeding, more patients receiving IV CEE (Premarin 25 mg in 5 mL isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> injected over two minutes with a dose repeated at three and five hours from the initial dose if bleeding continued) compared with placebo (lactose 200 mg) experienced cessation of bleeding after five hours of the first dose (72 versus 38 percent, respectively); at three hours bleeding cessation rates were similar between groups [<a href="#rid12">12</a>]. Among the five patients in the CEE group with continued bleeding at five hours, bleeding persisted in two patients at eight hours. Endometrial biopsy revealed no association between histology (ie, benign, neoplasia, endometritis) and success of therapy.</p><p>An antiemetic is often required with this regimen. We give <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a> IV 2.5 to 10 mg every three to four hours as needed, with a maximum dose of 40 mg/day. In the trial described above, IV CEE produced nausea and vomiting in 39 percent of treated patients compared with 13 percent in the placebo group [<a href="#rid12">12</a>]. </p><p>If bleeding does not subside after eight hours, IV estrogen should be stopped and other treatments (eg, uterine curettage) employed [<a href="#rid12">12</a>]. If bleeding subsides, IV estrogen is continued for a total of 24 hours, and then an oral regimen (typically a combined oral contraceptive taper) is prescribed. (See <a class="local">'Preferred: High-dose combined oral contraceptives'</a> below and <a class="local">'High-dose oral estrogen'</a> below.) </p><p class="headingAnchor" id="H2283059746"><span class="h3">Subsequent line</span><span class="headingEndMark"> — </span>For patients with continued bleeding despite treatment with first line or alternate therapies, uterine artery embolization (UAE) or <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> may be used. (See <a class="local">'Role of uterine artery embolization'</a> below and <a class="local">'Tranexamic acid'</a> below.)</p><p class="headingAnchor" id="H22"><span class="h3">Last line: Hysterectomy</span><span class="headingEndMark"> — </span>In the rare case in which the above measures fail, hysterectomy is a last resort. (See  <a class="medical medical_review" href="/d/html/3311.html" rel="external">"Hysterectomy: Abdominal (open) route", section on 'Emergency or unplanned hysterectomy'</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">MANAGING HEMODYNAMICALLY STABLE PATIENTS</span><span class="headingEndMark"> — </span>Acute uterine bleeding in hemodynamically stable patients is usually self-limited. In such cases, immediate treatment is often not required, and a complete evaluation can be completed prior to starting treatment. (See <a class="local">'Further evaluation of hemodynamically stable patients'</a> above and  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a>.)</p><p class="headingAnchor" id="H2958369564"><span class="h2">Preferred: High-dose combined oral contraceptives</span><span class="headingEndMark"> — </span>For hemodynamically stable patients with acute uterine bleeding and no contraindications to estrogen therapy (see <a class="local">'Patients at risk of thrombosis'</a> below), and in whom a waiting period of 48 hours is not likely to result in additional medical complications, we use high doses of oral contraceptives (OCs)  (<a class="graphic graphic_algorithm graphicRef135252" href="/d/graphic/135252.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef142886" href="/d/graphic/142886.html" rel="external">table 4</a>). </p><p>We use a tapering regimen (eg, 35 mcg ethinyl estradiol-containing combination OC pill; five pills on day 1, four pills on day 2, three pills on day 3, two pills on day 4, and one pill on day 5); use of other formulations (eg, 30 and 50 mcg ethinyl estradiol-containing pills) and tapers have been described [<a href="#rid1">1,13</a>]. In most patients, bleeding will subside within 48 hours [<a href="#rid1">1,14</a>]. For patients with moderate bleeding, we start with three pills daily. To improve tolerability, the pills may be taken several hours apart and an antiemetic medication (eg, <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a> 12.5 to 25 mg per rectum) should be prescribed.</p><p>Treatment with one pill daily (omitting inactive [placebo] tablets) of the OC should continue for one to three weeks after the bleeding subsides and then should be stopped for three to five days to allow for a withdrawal bleed. Standard-dose OCs may then be restarted, either as a monthly or extended cycle regimen, to prevent recurrent menorrhagia or for contraception.</p><p>Other combined estrogen-progestin contraceptives (vaginal ring, patch) are <strong>not</strong> used for treatment of an episode of acute uterine bleeding since it is not possible to vary the dose as precisely as with OCs.</p><p>There are no data comparing treatment of estrogen-progestins with estrogen alone in patients with acute uterine bleeding. As discussed below (see <a class="local">'High-dose oral estrogen'</a> below), physiologically it appears that treatment with estrogen alone is likely to be effective more rapidly than with a combined estrogen-progestin; however, some patients prefer OCs due to familiarity or other reasons. </p><p class="headingAnchor" id="H1462145343"><span class="h2">Alternatives</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_algorithm graphicRef135252" href="/d/graphic/135252.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef142886" href="/d/graphic/142886.html" rel="external">table 4</a>)</p><p class="headingAnchor" id="H3961204103"><span class="h3">High-dose oral estrogen</span><span class="headingEndMark"> — </span>High-dose oral estrogen is an alternative to high-dose combined OCs and may be used in patients without contraindications to estrogen therapy in whom a waiting period of 48 hours is <strong>not</strong> acceptable, or those who prefer to avoid OCs. We give <a class="drug drug_general" data-topicid="9424" href="/d/drug information/9424.html" rel="external">conjugated equine estrogen</a> 2.5 mg every six hours [<a href="#rid15">15</a>]. This dose is equivalent to 8 to 40 mcg of ethinyl estradiol [<a href="#rid16">16</a>] and is therefore similar to or less than one dose of a 35 mcg OC. When bleeding subsides or is minimal, the dose may be decreased to 2.5 mg orally twice daily. Total duration of use is 21 to 25 days. Many patients experience nausea and vomiting while taking high-dose estrogen. An antiemetic (eg, <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a> 12.5 to 25 mg per rectum) should be prescribed, to be used as needed [<a href="#rid14">14</a>]. </p><p>There are no data regarding the time course of therapeutic success with high-dose oral estrogen. Based on the data for intravenous (IV) estrogen therapy and allowing for a delayed onset of action with oral administration, bleeding is likely to stop in most patients within 10 hours after the first dose. (See <a class="local">'Alternative: High-dose intravenous estrogen'</a> above.)</p><p>After the estrogen is discontinued, a progestin should be given; we use oral <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (10 mg/day) for 10 days. Administration of progestin concomitantly with estrogen for the last 7 to 10 days also been described [<a href="#rid17">17</a>].</p><p>Estrogen therapy alone may be more effective than combined estrogen-progestin or progestin-alone therapy because progestins inhibit the synthesis of estrogen receptors and increase estradiol dehydrogenase, thereby impeding the rapid proliferation of endometrium induced by estrogen. (See <a class="local">'Preferred: High-dose combined oral contraceptives'</a> above.)</p><p class="headingAnchor" id="H26"><span class="h3">Oral progestins</span><span class="headingEndMark"> — </span>For hemodynamically stable patients in whom the suspected etiology of acute bleeding is from anovulation, progestins rather than high-dose estrogen may be used as first line therapy. In such patients with a thickened endometrium, progestins inhibit further endometrial growth and organize and support the estrogen-primed endometrium, allowing effective sloughing upon hormone withdrawal [<a href="#rid7">7</a>]. By contrast, if acute bleeding has resulted in a denuded endometrium, progestins are unlikely to be effective. Diagnosis of anovulation is discussed separately. </p><p>In our practice, we use <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (MPA; 20 mg three times daily), but other dosing (eg, MPA 10 mg three times daily) and progestins (eg, <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> 20 to 60 mg two times daily; <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> 5 mg once to four times daily) have been described [<a href="#rid1">1,13,18,19</a>]. Dose selection is based on shared decision-making and tolerance of side effects. </p><p>Progestins are typically continued for at least 5 to 10 days. In anemic patients who can tolerate this regimen, a one- to two-month treatment period in conjunction with iron allows an increase in hemoglobin/hematocrit (see  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Response to iron supplementation'</a>). Prolonged use of these drugs can cause acne, mood changes, weight gain, headache, and lipid abnormalities.</p><p>In a randomized trial including 40 patients with acute uterine bleeding, treatment with <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (20 mg three times daily for seven days) compared with combined estrogen-progestin therapy (ethinyl estradiol 35 mcg and <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> 1 mg three times daily for seven days) resulted in cessation of bleeding in approximately three days in both groups [<a href="#rid1">1</a>]. To our knowledge, no trials have compared <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> with combined estrogen-progestin therapy or MPA for this indication.</p><p class="headingAnchor" id="H188812302"><span class="h3">Surgical management</span><span class="headingEndMark"> — </span>For hemodynamically stable patients who prefer to avoid hormonal therapies or in whom medical therapy is contraindicated or unsuccessful, surgical management (ie, endometrial ablation, uterine curettage, uterine artery embolization [UAE]) may be performed; hysterectomy is reserved for patients who strongly desire definitive surgical management. We prefer endometrial ablation rather than uterine curettage or UAE in patients in whom malignancy has been excluded <strong>and</strong> in those who have completed future childbearing. Endometrial ablation is an effective alternative treatment [<a href="#rid20">20-24</a>], and is more likely to provide long-term improvement in uterine bleeding symptoms, compared with other minimally invasive surgical therapies. An exception is patients in whom future childbearing is desired. In such patients, curettage is preferred as pregnancy is contraindicated following endometrial ablation and the safety of pregnancy following UAE is uncertain. If ablation is performed, patients must be counseled that contraception will be necessary following the procedure. (See <a class="local">'Preferred: Uterine curettage'</a> above and <a class="local">'Role of uterine artery embolization'</a> below.)</p><p>Hysteroscopy prior to ablation may be useful to identify and treat endometrial polyps or intracavitary leiomyomas. (See  <a class="medical medical_review" href="/d/html/3316.html" rel="external">"Overview of endometrial ablation"</a>.)</p><p>The potential efficacy of endometrial ablation was illustrated in a report of 26 patients with acute uterine bleeding who underwent ablation [<a href="#rid20">20</a>]. At one-year follow-up, 25 of 26 patients reported decreased bleeding and did not require further medical or surgical therapy; one patient required a hysterectomy after 16 months in the setting of a leiomyoma and persistent uterine bleeding. The efficacy of endometrial ablation in other patients (ie, patients with heavy menstrual bleeding) are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3316.html" rel="external">"Overview of endometrial ablation", section on 'Outcomes'</a>.)</p><p class="headingAnchor" id="H4199179554"><span class="h2">Subsequent line</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef142886" href="/d/graphic/142886.html" rel="external">table 4</a>)</p><p class="headingAnchor" id="H1039036"><span class="h3">Gonadotropin-releasing hormone analogs</span><span class="headingEndMark"> — </span>Gonadotropin-releasing hormone (GnRH) analogs, including agonists and antagonists, can be used in the treatment of acute uterine bleeding but are not first-line treatments. They are used more commonly as second- or third-line therapy to prevent abnormal uterine bleeding or as a temporizing measure until surgical intervention can be performed. Their use is limited by expense and adverse effects. (See  <a class="medical medical_review" href="/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>GnRH agonists</strong> – There are few reports of GnRH agonists for treatment of an acute episode of uterine bleeding [<a href="#rid17">17,25</a>]. Use of these agents may be considered in this setting if other methods have failed or are contraindicated. If they are used, they result in an initial follicle-stimulating hormone and luteinizing hormone surge that can lead to an increased volume of bleeding. Use of GnRH agonists in combination with other agents (eg, OCs) may avoid this surge. However, because of the potential for increased bleeding initially, GnRH agents should be used only in patients who can tolerate several days of heavy uterine bleeding. In our experience, treatment with GnRH agonists results in a decrease in the volume of bleeding within one week.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GnRH antagonists</strong> – GnRH antagonists are a relatively new generation of drug therapy, and, unlike GnRH agonists, a surge in gonadotropins is not observed. Two of these drugs, <a class="drug drug_general" data-topicid="118522" href="/d/drug information/118522.html" rel="external">elagolix</a> and relugolix, have been shown to reduce heavy menstrual bleeding associated with uterine fibroids [<a href="#rid26">26,27</a>]. This is discussed in more detail separately (see  <a class="medical medical_review" href="/d/html/5478.html" rel="external">"Uterine fibroids (leiomyomas): Treatment overview", section on 'GnRH analogs'</a>). However, use of GnRH antagonists for treatment of an acute episode of uterine bleeding has not yet been reported. </p><p></p><p class="headingAnchor" id="H27"><span class="h3">Tranexamic acid</span><span class="headingEndMark"> — </span>Another medical therapy option is <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> (eg, 1.3 g orally three times daily for up to five days), which acts within two to three hours of administration [<a href="#rid13">13,28</a>]. The drug exerts an antifibrinolytic effect by reversibly blocking lysine binding sites on plasminogen, thereby preventing fibrin degradation. Side effects from tranexamic acid include nausea, dizziness, and diarrhea.</p><p><a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">Tranexamic acid</a> was approved by the US Food and Drug Administration in 2009 for treatment of menorrhagia [<a href="#rid29">29</a>]. The risk of thrombotic events with tranexamic acid is controversial [<a href="#rid30">30-36</a>]. We use tranexamic acid only when other options have been unsuccessful and only in patients who are not at a high risk of thrombosis. It therefore has limited use in patients with contraindications to hormonal therapy since these are mainly due to risk of thrombosis. (See <a class="local">'Patients at risk of thrombosis'</a> below.)</p><p>While <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> may be used to reduce blood loss during open myomectomy, its use to stop excessive uterine bleeding in the outpatient setting appears to be limited [<a href="#rid37">37</a>]. The American College of Obstetricians and Gynecologists (ACOG) guidelines mention using IV tranexamic acid at a dose of 10 mg/kg (maximum 600 mg/dose) every eight hours [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H215243705"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H4026344290"><span class="h2">Role of uterine artery embolization</span><span class="headingEndMark"> — </span>For patients in whom the suspected etiology of acute bleeding is from a uterine arteriovenous (AV) malformation, uterine artery embolization (UAE) rather than uterine curettage may be used as first line therapy since it is an effective treatment for this condition. UAE can also be used as an effective alternative to hysterectomy in patients who wish to preserve their uterus.</p><p>Use of UAE in hemodynamically unstable patients is otherwise limited because it usually cannot be performed as rapidly as other measures. </p><p>The safety of pregnancy after UAE is uncertain and may be associated with adverse outcomes (eg, miscarriage, preterm birth, placental problems, malpresentation) in some pregnancies. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3299.html" rel="external">"Uterine fibroids (leiomyomas): Treatment with uterine artery embolization", section on 'Reproductive outcomes'</a>.)</p><p class="headingAnchor" id="H29"><span class="h2">Patients at risk of thrombosis</span><span class="headingEndMark"> — </span>Potential complications of estrogen therapy include venous thromboembolism (VTE) and coronary or cerebral thrombosis. Thus, estrogen therapy is contraindicated in patients at high risk for such complications  (<a class="graphic graphic_table graphicRef59759" href="/d/graphic/59759.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a> and  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>.)</p><p>By contrast, some patients with relative contraindications to estrogen therapy can be safely treated with estrogen for a short period (ie, ≤4 weeks), including those without vascular or thrombotic complications but with the following conditions (this list is not comprehensive):</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic lupus erythematosus</p><p class="bulletIndent1"><span class="glyph">●</span>Smoking</p><p></p><p>For patients in whom it is uncertain whether short-term estrogen therapy is safe, their primary care clinician should be consulted before initiating therapy. All patients should be counseled about the potential risks of estrogen therapy and instructed regarding warning signs of potential thrombotic events (eg, asymmetric swelling of an extremity, chest pain, shortness of breath) and monitored closely for these symptoms.</p><p>Large epidemiologic studies have not identified an increased risk of stroke, myocardial infarction, or VTE with use of progestin-only contraceptives. However, <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> acetate can be converted in the body to ethinyl estradiol, so use of this progestin should be avoided in high-risk patients [<a href="#rid38">38</a>]. The risk of thrombotic events with <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> is controversial. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Cardiovascular and thromboembolic risk'</a> and <a class="local">'Tranexamic acid'</a> above.)</p><p>Patients who are not candidates for hormonal or <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> therapy are treated surgically (see <a class="local">'Preferred: Uterine curettage'</a> above and <a class="local">'Surgical management'</a> above and <a class="local">'Role of uterine artery embolization'</a> above). Such patients who are also on anticoagulant therapy require appropriate perioperative management of these medications. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p class="headingAnchor" id="H4029270723"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109362.html" rel="external">"Society guideline links: Abnormal uterine bleeding"</a>.)</p><p class="headingAnchor" id="H18239935"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15420.html" rel="external">"Patient education: Heavy periods (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/8405.html" rel="external">"Patient education: Heavy or prolonged menstrual bleeding (menorrhagia) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – Acute uterine bleeding is excessively heavy or prolonged bleeding of uterine origin sufficient in volume to require urgent or emergency intervention. It may occur in reproductive-age patients with ovulatory or anovulatory bleeding and be an isolated episode or recurrent. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of evaluation</strong> – The goals of evaluation of patients who present with acute bleeding are to establish hemodynamic stability, exclude pregnancy, identify the source of bleeding, and evaluate whether the bleeding requires immediate medical and/or surgical treatment. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endometrial sampling</strong> – Endometrial sampling is performed in select nonpregnant reproductive-age patients and all postmenopausal patients with acute uterine bleeding to exclude endometrial hyperplasia/neoplasia  (<a class="graphic graphic_table graphicRef58600" href="/d/graphic/58600.html" rel="external">table 2</a>). Whether sampling is performed before, during, or after treatment depends on the choice of initial therapy and whether the patient's hemodynamic status allows therapy to be deferred while sampling is performed. (See <a class="local">'Further evaluation of hemodynamically stable patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamically unstable patients</strong> – For hemodynamically unstable patients with acute uterine bleeding  (<a class="graphic graphic_algorithm graphicRef135253" href="/d/graphic/135253.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial stabilization includes obtaining vascular access and blood product replacement. (See <a class="local">'Stabilizing the patient'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients, we suggest uterine curettage rather than medical therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Uterine curettage can be performed rapidly and is both diagnostic and therapeutic (cessation or decreased bleeding is expected in less than one hour). Patients with a suspected uterine arteriovenous malformation may be managed differently. (See <a class="local">'Preferred: Uterine curettage'</a> above and <a class="local">'Role of uterine artery embolization'</a> above.)</p><p></p><p class="bulletIndent2">Intrauterine tamponade may be used in conjunction with administration of blood products while more definitive therapy (eg, transfer to a high-acuity setting, preparation for uterine curettage, arrival of a surgeon) is implemented, or after completion of uterine curettage should bleeding continue. (See <a class="local">'Role of intrauterine tamponade'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with persistent bleeding after uterine curettage or prevention of recurrent bleeding, or for those in whom a waiting period of three or more hours is not likely to result in the need for additional blood product transfusion or medical complications, we suggest intravenous <a class="drug drug_general" data-topicid="9424" href="/d/drug information/9424.html" rel="external">conjugated equine estrogens</a> (CEE) alone rather than other medical or surgical therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Alternative: High-dose intravenous estrogen'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hysterectomy is reserved for patients in whom all other treatments are unsuccessful. (See <a class="local">'Last line: Hysterectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamically stable patients</strong>  (<a class="graphic graphic_algorithm graphicRef135252" href="/d/graphic/135252.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef142886" href="/d/graphic/142886.html" rel="external">table 4</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For hemodynamically stable patients with acute uterine bleeding we suggest high-dose combined oral contraceptives (OCs) rather than treatment with high-dose oral estrogens alone, progestins, or <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, OCs compared with oral estrogen alone may take longer to be effective. Other reasonable alternatives include progestin therapy for patients with anovulatory bleeding and a thickened endometrium or high-dose oral estrogen for those who prefer to avoid OCs. (See <a class="local">'Preferred: High-dose combined oral contraceptives'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients in whom medical therapy is contraindicated or unsuccessful, we suggest endometrial ablation rather than uterine curettage or uterine artery embolization (UAE (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>)). However, ablation should only be performed in patients in whom malignancy has been excluded and in those who have completed childbearing. For patients who have not completed childbearing, uterine curettage is preferred. (See <a class="local">'Surgical management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients at high risk for thrombosis</strong> – Estrogen therapy and <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> are contraindicated in patients at a high risk of thrombosis  (<a class="graphic graphic_table graphicRef59759" href="/d/graphic/59759.html" rel="external">table 5</a>). In such patients, we suggest treatment with progestins or surgery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients at risk of thrombosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Munro MG, Mainor N, Basu R, et al. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol 2006; 108:924.</a></li><li><a class="nounderline abstract_t">Mansfield PK, Voda A, Allison G. Validating a pencil-and-paper measure of perimenopausal menstrual blood loss. Womens Health Issues 2004; 14:242.</a></li><li><a class="nounderline abstract_t">Medical devices; labeling for menstrual tampon for the "ultra" absorbency. Food and Drug Administration, HHS. Final rule. Fed Regist 2000; 65:62282.</a></li><li class="breakAll">Rhoades R, Bell D. Physiology: Principles for Clinical Medicine, Lippincott Williams &amp; Wilkins, 2009.</li><li><a class="nounderline abstract_t">Grimes DA. Estimating vaginal blood loss. J Reprod Med 1979; 22:190.</a></li><li><a class="nounderline abstract_t">Parks JK, Elliott AC, Gentilello LM, Shafi S. Systemic hypotension is a late marker of shock after trauma: a validation study of Advanced Trauma Life Support principles in a large national sample. Am J Surg 2006; 192:727.</a></li><li><a class="nounderline abstract_t">March CM. Bleeding problems and treatment. Clin Obstet Gynecol 1998; 41:928.</a></li><li><a class="nounderline abstract_t">Haynes PJ, Hodgson H, Anderson AB, Turnbull AC. Measurement of menstrual blood loss in patients complaining of menorrhagia. Br J Obstet Gynaecol 1977; 84:763.</a></li><li><a class="nounderline abstract_t">Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG Committee Opinion No. 785. Obstet Gynecol 2019; 134:e71. Reaffirmed 2023.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol 2013; 121:891. Reaffirmed 2021.</a></li><li><a class="nounderline abstract_t">Zreik TG, Odunsi K, Cass I, et al. A case of fatal pulmonary thromboembolism associated with the use of intravenous estrogen therapy. Fertil Steril 1999; 71:373.</a></li><li><a class="nounderline abstract_t">DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study. Obstet Gynecol 1982; 59:285.</a></li><li><a class="nounderline abstract_t">James AH, Kouides PA, Abdul-Kadir R, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol 2011; 158:124.</a></li><li><a class="nounderline abstract_t">Shwayder JM. Pathophysiology of abnormal uterine bleeding. Obstet Gynecol Clin North Am 2000; 27:219.</a></li><li class="breakAll">https://www.studocu.com/row/document/fiji-national-university/mbbs-year-2/abnormal-uterine-bleeding/17848520 (Accessed on June 27, 2023).</li><li class="breakAll">Speroff L, Fritz M. Postmenopausal hormone therapy. In: Clinical Gynecologic Endocrinology and Infertility, 7th ed, Speroff L, Fritz M (Eds), Lippincott Williams &amp; Wilkins, 2005.</li><li><a class="nounderline abstract_t">Chuong CJ, Brenner PF. Management of abnormal uterine bleeding. Am J Obstet Gynecol 1996; 175:787.</a></li><li><a class="nounderline abstract_t">Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. JAMA 1993; 269:1823.</a></li><li><a class="nounderline abstract_t">Aksu F, Madazli R, Budak E, et al. High-dose medroxyprogesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents. Aust N Z J Obstet Gynaecol 1997; 37:228.</a></li><li><a class="nounderline abstract_t">Franchini M, Cianferoni L. Emergency endometrial resection in women with acute, severe uterine bleeding. J Am Assoc Gynecol Laparosc 2000; 7:347.</a></li><li><a class="nounderline abstract_t">Milad MP, Valle RF. Emergency endometrial ablation for life-threatening uterine bleeding as a result of a coagulopathy. J Am Assoc Gynecol Laparosc 1998; 5:301.</a></li><li><a class="nounderline abstract_t">Nichols CM, Gill EJ. Thermal balloon endometrial ablation for management of acute uterine hemorrhage. Obstet Gynecol 2002; 100:1092.</a></li><li><a class="nounderline abstract_t">Osuga Y, Okagaki R, Ozaki S, et al. Successful emergency endometrial ablation for intractable uterine bleeding in a postmenopausal woman complicated with liver cirrhosis and morbid obesity. Surg Endosc 2001; 15:898.</a></li><li><a class="nounderline abstract_t">Richards SR. Endometrial ablation for life-threatening abnormal uterine bleeding. A report of two cases. J Reprod Med 1994; 39:741.</a></li><li><a class="nounderline abstract_t">Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol 2016; 214:31.</a></li><li><a class="nounderline abstract_t">Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med 2020; 382:328.</a></li><li><a class="nounderline abstract_t">Simon JA, Al-Hendy A, Archer DF, et al. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol 2020; 135:1313.</a></li><li><a class="nounderline abstract_t">Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995; 102:401.</a></li><li class="breakAll">FDA Approves Lysteda to Treat Heavy Menstrual Bleeding. US Food and Drug Administration. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm190551.htm (Accessed on February 17, 2010).</li><li><a class="nounderline abstract_t">Sundström A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 2009; 116:91.</a></li><li><a class="nounderline abstract_t">Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 2002; 68:307.</a></li><li><a class="nounderline abstract_t">Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2001; 99:238.</a></li><li><a class="nounderline abstract_t">Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 2003; 63:1417.</a></li><li><a class="nounderline abstract_t">Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001; 86:714.</a></li><li><a class="nounderline abstract_t">Iacobellis G, Iacobellis G. Combined treatment with tranexamic acid and oral contraceptive pill causes coronary ulcerated plaque and acute myocardial infarction. Cardiovasc Drugs Ther 2004; 18:239.</a></li><li><a class="nounderline abstract_t">Fraser IS, Porte RJ, Kouides PA, Lukes AS. A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding. Drug Saf 2008; 31:275.</a></li><li><a class="nounderline abstract_t">Opoku-Anane J, Vargas MV, Moawad G, et al. Use of Intravenous Tranexamic Acid During Myomectomy: A Randomized Double-Blind Placebo Controlled Trial. J Minim Invasive Gynecol 2015; 22:S197.</a></li><li><a class="nounderline abstract_t">Chu MC, Zhang X, Gentzschein E, et al. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab 2007; 92:2205.</a></li></ol></div><div id="topicVersionRevision">Topic 5415 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17012455" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589775" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Validating a pencil-and-paper measure of perimenopausal menstrual blood loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11503680" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Medical devices; labeling for menstrual tampon for the "ultra" absorbency. Food and Drug Administration, HHS. Final rule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11503680" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Medical devices; labeling for menstrual tampon for the "ultra" absorbency. Food and Drug Administration, HHS. Final rule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/458761" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Estimating vaginal blood loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17161083" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Systemic hypotension is a late marker of shock after trauma: a validation study of Advanced Trauma Life Support principles in a large national sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9917948" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Bleeding problems and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/921913" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Measurement of menstrual blood loss in patients complaining of menorrhagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31441825" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23635706" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988414" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A case of fatal pulmonary thromboembolism associated with the use of intravenous estrogen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6281704" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21632169" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10857116" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pathophysiology of abnormal uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10857116" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pathophysiology of abnormal uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10857116" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pathophysiology of abnormal uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8828563" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Management of abnormal uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8459515" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical manifestations and treatment of dysfunctional uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9222474" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : High-dose medroxyprogesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10924628" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Emergency endometrial resection in women with acute, severe uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9668155" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Emergency endometrial ablation for life-threatening uterine bleeding as a result of a coagulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12423817" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Thermal balloon endometrial ablation for management of acute uterine hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443433" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Successful emergency endometrial ablation for intractable uterine bleeding in a postmenopausal woman complicated with liver cirrhosis and morbid obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7807491" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Endometrial ablation for life-threatening abnormal uterine bleeding. A report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26254516" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The medical management of abnormal uterine bleeding in reproductive-aged women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31971678" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32459423" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7612535" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7612535" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016686" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12144537" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11788179" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12825966" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tranexamic acid: a review of its use in the management of menorrhagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11522029" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : No increased risk of venous thrombosis in women taking tranexamic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229393" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Combined treatment with tranexamic acid and oral contraceptive pill causes coronary ulcerated plaque and acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18366238" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27679021" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Use of Intravenous Tranexamic Acid During Myomectomy: A Randomized Double-Blind Placebo Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17341557" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Formation of ethinyl estradiol in women during treatment with norethindrone acetate.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
